Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
PS-48 is an allosteric modulator/activator of the phosphoinositide-dependent protein kinase-1 (PDK1) with Kd of 10.3 μM. It binds exclusively to the PIF-binding pocket of PDK1, which is distinct from the conserved ATP binding site. The activation of AKT/PKB and numerous other AGC kinases, such as PKC, S6K, and SGK, depends on the master kinase PDPK1. In the signaling pathways triggered by a number of growth factors and hormones, including insulin signaling, PDPK1 plays a significant role.
Targets |
PDPK1
|
---|---|
ln Vitro |
The PDK1 agonist PS48 has the power to enhance the osteogenic capacity of dexamethasone-treated MC3T3-E1 cells. In MC3T3-E1 cells treated with dexamethasone after PS48 treatment, the protein levels of p-AKT and p-mTOR are elevated. [2]
|
ln Vivo |
In vivo, the PDK1 agonist PS48 can maintain the bone mass of mice treated with dexamethasone.[2]
|
Cell Assay |
MC3T3-E1 cells are cultured in an osteogenic differentiation medium containing 4 mM glycerophosphate and 25 g/mL ascorbic acid until 70% confluency. The osteogenic differentiation medium is then supplemented for 14 days with dexamethasone (final ethanol concentration, 0.01%, vol/vol) at various concentrations. Every two days, the culture medium is changed. Dexamethasone 107 M culture medium supplemented with or without PS48 (5 M) is used to cultivate MC3T3-E1 cells.
|
Animal Protocol |
8-week-old male C57BL/6J mice
|
References |
Molecular Formula |
C17H15CLO2
|
|
---|---|---|
Molecular Weight |
286.75
|
|
Exact Mass |
286.0761
|
|
Elemental Analysis |
C, 71.21; H, 5.27; Cl, 12.36; O, 11.16
|
|
CAS # |
1180676-32-7
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
C1=CC=C(C=C1)/C(=C\C(=O)O)/CCC2=CC=C(C=C2)Cl
|
|
InChi Key |
LLJYFDRQFPQGNY-QINSGFPZSA-N
|
|
InChi Code |
InChI=1S/C17H15ClO2/c18-16-10-7-13(8-11-16)6-9-15(12-17(19)20)14-4-2-1-3-5-14/h1-5,7-8,10-12H,6,9H2,(H,19,20)/b15-12-
|
|
Chemical Name |
(Z)-5-(4-chlorophenyl)-3-phenylpent-2-enoic acid
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~57 mg/mL (~198.8 mM)
Ethanol: ~57 mg/mL (~198.8 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.4874 mL | 17.4368 mL | 34.8736 mL | |
5 mM | 0.6975 mL | 3.4874 mL | 6.9747 mL | |
10 mM | 0.3487 mL | 1.7437 mL | 3.4874 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05546385 | Recruiting | Device: Sham breathing device Device: Partial Rebreathing Device |
Migraine With Aura | Rehaler | June 16, 2023 |